Fig. 2: Body weight over time. | Nature Medicine

Fig. 2: Body weight over time.

From: Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

Fig. 2

Children achieved the ability to maintain weight at or greater than the 3rd percentile, without the need for non-oral or mechanical feeding support at any visit up to 18 months of age for female (a) and male (b) individuals, according to the WHO child growth standards25. Gray shading represents WHO growth standards for the 3rd through 97th percentiles. n = 4 males and n = 10 females; mean (s.d.) age at dosing, 20.6 (7.9) days.

Back to article page